PT2424559T - Métodos de tratamento de infeções bacterianas utilizando oritavancina - Google Patents
Métodos de tratamento de infeções bacterianas utilizando oritavancinaInfo
- Publication number
- PT2424559T PT2424559T PT107724932T PT10772493T PT2424559T PT 2424559 T PT2424559 T PT 2424559T PT 107724932 T PT107724932 T PT 107724932T PT 10772493 T PT10772493 T PT 10772493T PT 2424559 T PT2424559 T PT 2424559T
- Authority
- PT
- Portugal
- Prior art keywords
- oritavancin
- methods
- bacterial infections
- treating bacterial
- treating
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 title 1
- 229960001607 oritavancin Drugs 0.000 title 1
- 108010006945 oritavancin Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17345109P | 2009-04-28 | 2009-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2424559T true PT2424559T (pt) | 2024-04-30 |
Family
ID=43050709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107724932T PT2424559T (pt) | 2009-04-28 | 2010-04-26 | Métodos de tratamento de infeções bacterianas utilizando oritavancina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9682061B2 (enExample) |
| EP (1) | EP2424559B1 (enExample) |
| JP (1) | JP2012525391A (enExample) |
| CN (1) | CN102573882A (enExample) |
| AU (1) | AU2010245097B2 (enExample) |
| BR (1) | BRPI1014767A2 (enExample) |
| CA (1) | CA2760159C (enExample) |
| ES (1) | ES2981472T3 (enExample) |
| PL (1) | PL2424559T3 (enExample) |
| PT (1) | PT2424559T (enExample) |
| WO (1) | WO2010129233A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3006038T3 (pl) * | 2008-08-30 | 2024-11-12 | The Medicines Company | Pojedyncze dawki orytawancyny do leczenia zakażenia bakteryjnego lub zapobiegania takiemu zakażeniu |
| CN103119958A (zh) * | 2010-07-20 | 2013-05-22 | 夏普株式会社 | 内容分发装置、内容重放装置、内容分发系统、内容分发装置的控制方法、控制程序以及记录介质 |
| WO2016011245A1 (en) | 2014-07-17 | 2016-01-21 | The Medicines Company | High purity oritavancin and method of producing same |
| US10534895B2 (en) * | 2015-01-20 | 2020-01-14 | Icpd Technologies, Llc | System and method for ranking options for medical treatments |
| HUE069322T2 (hu) * | 2016-02-18 | 2025-03-28 | Melinta Therapeutics Llc | Oritavancin készítmények |
| GB2577420B (en) * | 2017-05-22 | 2022-07-06 | Insmed Inc | Glycopeptide derivative compounds and uses thereof |
| KR102189125B1 (ko) * | 2018-11-30 | 2020-12-10 | 주식회사 리얼타임테크 | 로그 수집 시스템 및 그 수집 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750509A (en) | 1991-07-29 | 1998-05-12 | Gruppo Lepetit S.P.A. | Amide derivatives of antibiotic A 40926 |
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| JP4870314B2 (ja) | 2000-05-02 | 2012-02-08 | セラヴァンス， インコーポレーテッド | シクロデキストリンを含むグリコペプチド抗生物質組成物 |
| UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| US20030176327A1 (en) * | 2001-10-25 | 2003-09-18 | Cassell Gail Houston | Antibiotics for treating biohazardous bacterial agents |
| AU2007346657B2 (en) * | 2006-09-25 | 2013-07-11 | Targanta Therapeutics Corp. | Use of oritavancin for prevention and treatment of anthrax |
| WO2008118784A1 (en) | 2007-03-23 | 2008-10-02 | Targanta Therapeutics Corp. | Glycopeptide and lipoglycopeptide antibiotics with improved solubility |
| EP2195004B1 (en) * | 2007-09-12 | 2015-04-01 | The Medicines Company | Method of inhibiting clostridium difficile by administration of oritavancin |
| PL3006038T3 (pl) | 2008-08-30 | 2024-11-12 | The Medicines Company | Pojedyncze dawki orytawancyny do leczenia zakażenia bakteryjnego lub zapobiegania takiemu zakażeniu |
-
2010
- 2010-04-26 US US12/740,571 patent/US9682061B2/en active Active
- 2010-04-26 CA CA2760159A patent/CA2760159C/en active Active
- 2010-04-26 CN CN2010800303023A patent/CN102573882A/zh active Pending
- 2010-04-26 BR BRPI1014767A patent/BRPI1014767A2/pt not_active Application Discontinuation
- 2010-04-26 ES ES10772493T patent/ES2981472T3/es active Active
- 2010-04-26 WO PCT/US2010/032441 patent/WO2010129233A2/en not_active Ceased
- 2010-04-26 PT PT107724932T patent/PT2424559T/pt unknown
- 2010-04-26 PL PL10772493.2T patent/PL2424559T3/pl unknown
- 2010-04-26 AU AU2010245097A patent/AU2010245097B2/en active Active
- 2010-04-26 EP EP10772493.2A patent/EP2424559B1/en active Active
- 2010-04-26 JP JP2012508570A patent/JP2012525391A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2760159A1 (en) | 2010-11-11 |
| AU2010245097A9 (en) | 2015-08-13 |
| AU2010245097B2 (en) | 2015-08-13 |
| US20120035097A1 (en) | 2012-02-09 |
| EP2424559B1 (en) | 2024-04-03 |
| CN102573882A (zh) | 2012-07-11 |
| EP2424559A4 (en) | 2012-10-03 |
| CA2760159C (en) | 2021-01-12 |
| ES2981472T3 (es) | 2024-10-09 |
| WO2010129233A2 (en) | 2010-11-11 |
| PL2424559T3 (pl) | 2024-07-29 |
| JP2012525391A (ja) | 2012-10-22 |
| AU2010245097A1 (en) | 2011-11-10 |
| BRPI1014767A2 (pt) | 2016-04-19 |
| EP2424559A1 (en) | 2012-03-07 |
| US9682061B2 (en) | 2017-06-20 |
| WO2010129233A9 (en) | 2011-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3269A (en) | Methods and compounds for treating paramyxoviridaevirus infections | |
| ZA201301598B (en) | Benzoxaborole derivatives for treating bacterial infections | |
| ZA201006648B (en) | Methods of treatment | |
| IL207170A0 (en) | Methods of treating viral infections | |
| ZA201005798B (en) | Treatment of microbial infections | |
| EP2350641A4 (en) | Methods of Treatment | |
| DK2473482T3 (en) | Methods of treating orthomyxoviral infections | |
| EP2453748A4 (en) | METHOD OF TREATMENT | |
| PL2424559T3 (pl) | Sposoby leczenia zakażeń bakteryjnych z zastosowaniem orytawancyny | |
| EP2473493A4 (en) | METHODS OF TREATING POXVIRAL INFECTIONS | |
| ZA201204249B (en) | Treatment of microbial infections | |
| WO2011146624A9 (en) | Methods of treating recurring bacterial infection | |
| PH12012500528A1 (en) | Compositions and methods for treating bacterial infections using caftaroline | |
| GB0801768D0 (en) | Treatment of microbial infections | |
| AU2009905173A0 (en) | Methods of treatment | |
| AU2009902633A0 (en) | Methods of treatment | |
| AU2009904460A0 (en) | Methods of treatment | |
| GB0807781D0 (en) | Treatment of bacterial infection | |
| AU2009903360A0 (en) | Method of Treatment | |
| GB0921823D0 (en) | Method of treatment | |
| GB0909807D0 (en) | Method of treatment | |
| GB0904164D0 (en) | Method of treatment | |
| GB0919711D0 (en) | Treatment of viral infections | |
| GB0913914D0 (en) | Treatment of viral infections | |
| AU2009900969A0 (en) | Treatment of infection |